Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
The combination of neoadjuvant chemotherapy and pembrolizumab resulted in a pCR rate of 31.7% in patients with non-metastatic TN-IBC. Compared with triple-negative non-IBC, the lower pCR rate with this combination regimen highlights the need for biomarkers for better patient selection and more active treatment options for this rare and aggressive breast cancer subtype.
Authors
- R.M. Layman
- W.A. Woodward
- J.M. Ribeiro
- E. Troll
- S. Ladoire
- T. Petit
- D. Trapani
- A. Lucci
- F. Nakhlis
- B. Pistilli
- C. Block
- L. Warren
- J. Bellon
- S. Ryan
- F. Bertucci
- O. Tredan
- S. Schumer
- K.A. Fanucci
- L.A. Carey
- C. Zemmour
- A. Goncalves
- M. Leheurteur
- S.M. Niman
- M. Kai
- M.M. Regan
- A. Giordano
- F. Lerebours
- F. Lynce
- F. Dalenc
- P. Zagami
- L. Lopez Almeida
- V. Valero
- C. Valenza
- C. Levy
- A. Nasrazadani
- T. Bachelot
- S. Krishnamurthy
- G. Curigliano
- S.M. Tolaney
Institutions
- University of North Carolina at Chapel Hill (US)
- The University of Texas MD Anderson Cancer Center (US)
- Institut Gustave Roussy (FR)
- Centre Georges François Leclerc (FR)
- Centre Léon Bérard (FR)
- Dana-Farber Cancer Institute (US)
- Centre François Baclesse (FR)
- Institut Claudius Regaud (FR)
- Dana-Farber/Harvard Cancer Center (US)
- Institut Paoli-Calmettes (FR)
- Centre Henri Becquerel (FR)
- European Institute of Oncology (IT)
- Institut Curie (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1016/j.esmoop.2025.106050
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00